Antibody-coated magnetic beads were crucial in the manufacturing process to achieve one-step cell isolation and activation, and enabled clinical-scale dose production within 2 to 3 weeks. Since then, the technology has become well established in the industry and has been used in over 200 clinical trials to provide critically needed treatment for patients. Despite these successes, challenges remain to further improve the reliability, consistency, and longevity of treatment outcomes. As well, there is still a need to accelerate and expand treatment delivery to patients. Download this application note to learn more how cell therapy system (CTS) Detachable Dynabeads CD3/CD28 were used to achieve one-step isolation and activation with flexible active release to optimize T cell phenotype.
Please check the highlighted fields and try again.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
By submitting this form, you consent to Cell & Gene Therapy Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.